Loading ...
Sorry, an error occurred while loading the content.

New Study Suggests Possible Clinical Benefit UsingNewer Test for

Expand Messages
  • claudine intexas
    Harriett, this is not the medical study I mentioned, I m still looking for that. This is just a news release, but it is about the same thing. New Study
    Message 1 of 1 , Dec 18, 2000
    • 0 Attachment
      Harriett, this is not the medical study I mentioned,
      I'm still looking for that. This is just a news
      release, but it is about the same thing.

      New Study Suggests Possible Clinical Benefit Using
      Newer Test for
      Detecting
      Hepatitis C


      TARRYTOWN, N.Y., Nov. 14 /PRNewswire/ -- A study
      presented at this
      year's
      51st American Association for the Study of Liver
      Disease (AASLD)
      meeting
      reported on results using a new Hepatitis C (HCV) test
      which utilizes a
      cutting-edge molecular diagnostics technology called
      transcription
      mediated amplification (TMA). The results of this
      study showed that
      more
      than one- third of the patient samples that tested
      negative for HCV
      using
      the conventional PCR test were actually positive when
      tested by the new
      TMA test.

      Dr. Stefan Zeuzem of the Zentrum der Inneren Medizin,
      Frankfurt,
      Germany,
      presented results of a study in which 47 patient
      samples that had
      previously tested negative for HCV with existing
      PCR-based assays, were
      re-tested with the VERSANT(TM) HCV Qualitative RNA
      Assay from Bayer
      Diagnostics. The results of this new study showed
      that 36% of patient
      samples that were negative using the PCR assay were
      positive by the new
      TMA test. After being tested with the conventional
      PCR test, all of
      these
      patients had relapsed after treatment was stopped.
      Dr. Zeuzem
      speculated
      that the results may have implications for the
      treatment of chronic
      Hepatitis C, such as keeping patients on therapy
      longer to avoid
      relapse.
      Further research is necessary to confirm these early
      stage results.

      The VERSANT(TM) HCV RNA Qualitative Assay, is
      currently available for
      Investigational Use Only (the performance
      characteristics of this
      product
      have not been established) in Germany and other parts
      of Europe.
      Qualitative testing for HCV using TMA technology is
      available in the
      U.S.
      as a service of the Bayer Reference Testing Laboratory
      in Emeryville,
      California.

      Bayer Diagnostics is a leader in developing novel
      nucleic acid
      diagnostic
      tests for infectious diseases. The company recently
      released a new
      version of its quantitative HCV RNA assay (based on
      its proprietary
      bDNA
      technology). That assay, VERSANT(TM) HCV RNA 3.0 Assay
      (bDNA) is
      available
      worldwide for Research Use Only (not for use for
      diagnostic
      procedures),
      and is designed to quantitate HCV RNA over a broad
      range of values.

      Bayer Diagnostics

      With more than 7,500 employees worldwide and 1999
      sales of close to
      $1.8
      billion, Bayer Diagnostics (www.bayerdiag.com), based
      in Tarrytown, New
      York, USA, is one of the largest diagnostic businesses
      in the world.
      The
      organization supports customers in 100 countries
      through an extensive
      portfolio of central laboratory, self-testing, nucleic
      acid, point of
      care
      and critical care diagnostics systems and services for
      use in the
      assessment and management of health, including the
      areas of
      cardiovascular
      disease, oncology, virology, women's health and
      diabetes. Bayer
      Diagnostics is a part of the worldwide Bayer Group, a
      $29 billion
      international life sciences, polymers and specialty
      chemicals group
      based
      in Leverkusen, Germany. Bayer Diagnostics' global
      headquarters in the
      United States operates as part of Bayer Corporation of
      Pittsburgh, a
      research-based company with major businesses in health
      care, life
      science
      and chemicals.

      SOURCE Bayer Corporation

      CO: Bayer Corporation; Bayer Diagnostics; American
      Association for the
      Study of Liver Disease

      ST: Pennsylvania, New York

      __________________________________________________
      Do You Yahoo!?
      Yahoo! Shopping - Thousands of Stores. Millions of Products.
      http://shopping.yahoo.com/
    Your message has been successfully submitted and would be delivered to recipients shortly.